| Literature DB >> 35440799 |
Yujia Qiao1, Amal A Wanigatunga2,3, Yang An4, Fangyu Liu2, Adam P Spira3,5,6, Christos Davatzikos7, Qu Tian4, Eleanor M Simonsick4, Luigi Ferrucci4, Susan M Resnick4, Jennifer A Schrack2,3.
Abstract
Peak energy capacity of the whole person is associated with neurodegeneration. However, change in ability to utilize energy manifests as combination of declining peak energy capacity and rising energetic costs of mobility in mid-to-late life. We examined longitudinal associations between change in energy utilization and brain volumes. Cognitively normal participants from the Baltimore Longitudinal Study of Aging (N = 703, age = 70.4 ± 12.1 years, 54.1% women, 30% black) had concurrent data on brain volumes and energy utilization (defined as ratio of energetic cost of walking to peak energy capacity ("cost-to-capacity ratio") at ≥ 1 visit between 2008 and 2018. We performed linear mixed-effect models, adjusting for demographics, medical history and walking engagement. Average baseline cost-to-capacity ratio was 0.55 ± 0.16, with average annual increase of 0.04 ± 0.13 over 3.9 follow-up years. A 10% higher baseline cost-to-capacity ratio was associated with 2.00 cm3 (SE = 0.44) larger baseline ventricular volume (p < 0.001), and 0.10 cm3 (SE = 0.03) greater annual increase in ventricular volume (p = 0.004) after adjustment. Longitudinal change in cost-to-capacity ratio was not associated with brain volumes. These findings highlight, among cognitive-normal adults, poorer baseline energy utilization is associated with subsequent ventricular enlargement, an indirect measure of central brain atrophy. Future studies should explore whether early detection of worsening energy utilization may act as a marker of underlying brain atrophy.Entities:
Mesh:
Year: 2022 PMID: 35440799 PMCID: PMC9018828 DOI: 10.1038/s41598-022-10421-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Baseline characteristics of 703 BLSA participants by baseline cost-to-capacity ratio (≤ 0.5 vs. > 0.5), defined as the energy cost of slow walking to peak walking energy expenditure.
| Overall | Baseline cost-to-capacity ratio ≤ 0.5 | Baseline cost-to-capacity ratio > 0.5 | p value | |
|---|---|---|---|---|
| Age (years) | 70.4 ± 12.2 | 66.1 ± 13.7 | 73.7 ± 9.8 | < 0.001 |
| Women | 380 (54.1) | 161 (53.5) | 219 (54.5) | 0.795 |
| White | 492 (70.0) | 218 (72.4) | 274 (68.2) | 0.222 |
| Education (years) | 17.0 ± 2.7 | 17.2 ± 2.5 | 16.9 ± 2.9 | 0.255 |
| Height, in cm | 167.6 ± 9.1 | 168.4 ± 8.9 | 167.0 ± 9.3 | 0.042 |
| Fat mass (kg) | 26.4 ± 9.6 | 24.8 ± 8.9 | 27.6 ± 10.0 | < 0.001 |
| Lean mass (kg) | 46.4 ± 9.8 | 47.3 ± 10.3 | 45.7 ± 9.3 | 0.028 |
| Current smoker | 12 (1.7) | 5 (1.66) | 7 (1.74) | 0.935 |
| Heavy drinkera | 119 (16.9) | 52 (17.28) | 67 (16.67) | 0.831 |
| 492 (70.0) | 198 (65.8) | 294 (73.1) | 0.035 | |
| Having high cholesterol | 421 (59.9) | 174 (57.8) | 247 (61.4) | 0.330 |
| Having osteoarthritis | 384 (54.6) | 150 (49.8) | 234 (58.2) | 0.027 |
| Having hypertensionb | 367 (52.2) | 133 (44.19) | 234 (58.21) | < 0.001 |
| Having cancer | 217 (30.9) | 86 (28.6) | 131 (32.6) | 0.254 |
| Having diabetesc | 111 (15.8) | 43 (14.29) | 68 (16.92) | 0.344 |
| Having COPD | 95 (13.5) | 38 (12.6) | 57 (14.2) | 0.551 |
| Having CVDd | 60 (8.5) | 16 (5.3) | 44 (11.0) | 0.008 |
| Having stroke | 28 (4.0) | 6 (2.0) | 22 (5.5) | 0.020 |
| CES-D (range 0–60) | 4.8 ± 5.1 | 4.3 ± 4.5 | 5.2 ± 5.4 | 0.013 |
| APOE e4 carriers | 173 (25.7) | 84 (29.07) | 89 (23.12) | 0.080 |
| Did brisk walking in the past 2 weeks | 264 (37.6) | 136 (45.2) | 128 (31.8) | < 0.001 |
| Intracranial volume (cm3) | 1391.6 ± 140.8 | 1395.1 ± 144.5 | 1389.0 ± 138.0 | 0.571 |
| Subsequent diagnosed MCI/dementia | 84 (11.9) | 27(8.97) | 57(14.18) | 0.035 |
| Follow-up time (years) | 3.9 ± 2.0 | 4.4 ± 2.0 | 3.6 ± 1.9 | 0.003 |
| 0.656 | ||||
| 1 | 304 (43.2) | 127 (42.2) | 177 (44.0) | |
| 2 | 209 (29.7) | 87 (28.9) | 122 (30.4) | |
| 3 | 123 (17.5) | 54 (17.9) | 69 (17.2) | |
| 4+ | 67 (9.5) | 33 (11.0) | 34 (8.5) | |
| Baseline cost-to-capacity ratio | 0.55 ± 0.16 | 0.40 ± 0.09 | 0.65 ± 0.12 | < 0.001 |
| Total brain | 1134.3 ± 115.3 | 1146.9 ± 117.6 | 1124.9 ± 112.7 | 0.012 |
| Gray matter | 611.7 ± 61.9 | 622.5 ± 62.9 | 603.6 ± 60.0 | < 0.001 |
| White matter | 465.5 ± 50.7 | 472.5 ± 52.8 | 460.3 ± 48.4 | 0.002 |
| Ventricles | 36.2 ± 22.5 | 30.8 ± 16.7 | 40.3 ± 25.3 | < 0.001 |
| Frontal lobe | 350.0 ± 38.6 | 356.0 ± 39.4 | 345.4 ± 37.4 | < 0.001 |
| Temporal lobe | 201.1 ± 22.4 | 204.1 ± 23.4 | 198.9 ± 21.5 | 0.002 |
| Parietal lobe | 172.9 ± 18.8 | 176.0 ± 19.6 | 170.7 ± 17.9 | < 0.001 |
| Occipital lobe | 114.7 ± 13.9 | 116.8 ± 14.3 | 113.1 ± 13.5 | 0.001 |
| Hippocampus | 7.4 ± 0.8 | 7.5 ± 0.8 | 7.3 ± 0.9 | 0.003 |
All reported in mean ± SD or frequency (%). SD standard deviation, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, CES-D Center for Epidemiologic Studies Depression Scale, MCI mild cognitive impair.
aDrinking more than 7 alcoholic drinks/week.
bSystolic blood pressure ≥ 130 mmHg and or diastolic blood pressure ≥ 80 mmHg, or a history of diagnosis plus treatment with antihypertensive medications.
cFasting glucose ≥ 126 mg/dL, or a history of a diagnosis plus treatment with oral antidiabetic drugs or insulin.
dCVD includes heart attack, angina, myocardial infarction, congestive heart failure, peripheral arterial disease, and vascular-related procedures (including coronary artery bypass grafting or angioplasty).
Longitudinal mixed models of the associations between energy utilization and brain volumes among 703 BLSA participantsa.
| Baseline cost-to-capacity ratio (A) | Baseline cost-to-capacity ratio × time (B) | Change in cost-to-capacity ratio (C) | Change in cost-to-capacity ratio × time (D) | Time (E) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| β (SE) | p-value | β (SE) | p-value | β (SE) | p-value | β (SE) | p-value | β (SE) | p-value | |
| Total brain | 0.260 (1.019) | 0.799 | 0.187 (0.167) | 0.262 | 0.520 (0.764) | 0.496 | − 0.030 (0.192) | 0.496 | − 3.58 (0.92) | < 0.001 |
| GM | − 0.948 (0.664) | 0.153 | 0.120 (0.134) | 0.370 | − 0.383 (0.602) | 0.525 | 0.115 (0.154) | 0.525 | − 3.55 (0.74) | < 0.001 |
| WM | − 0.330 (0.584) | 0.573 | − 0.057 (0.080) | 0.471 | 0.493 (0.384) | 0.200 | − 0.121 (0.094) | 0.200 | − 0.59 (0.44) | 0.181 |
| Ventricles | 0.055 (0.091) | 0.545 | 0.001 (0.024) | 0.545 | 0.89 (0.19) | < 0.001 | ||||
| Frontal lobe | − 0.178 (0.420) | 0.671 | − 0.015 (0.061) | 0.807 | 0.205 (0.279) | 0.463 | − 0.031 (0.070) | 0.463 | − 1.18 (0.34) | 0.001 |
| Frontal GM | − 0.187 (0.252) | 0.458 | 0.004 (0.044) | 0.932 | 0.008 (0.194) | 0.966 | 0.005 (0.050) | 0.966 | − 0.85 (0.24) | < 0.001 |
| Frontal WM | 0.031 (0.264) | 0.906 | − 0.020 (0.033) | 0.556 | 0.200 (0.161) | 0.214 | − 0.036 (0.039) | 0.214 | − 0.31 (0.18) | 0.089 |
| Temporal lobe | − 0.375 (0.247) | 0.129 | 0.018 (0.037) | 0.637 | 0.087 (0.162) | 0.591 | − 0.015 (0.042) | 0.591 | − 0.91 (0.21) | < 0.001 |
| Temporal GM | − 0.202 (0.162) | 0.213 | 0.008 (0.029) | 0.784 | − 0.001 (0.121) | 0.993 | 0.004 (0.031) | 0.993 | − 0.70 (0.16) | < 0.001 |
| Temporal WM | − 0.158 (0.146) | 0.281 | 0.005 (0.020) | 0.787 | 0.094 (0.093) | 0.311 | − 0.021 (0.023) | 0.311 | − 0.17 (0.11) | 0.123 |
| Parietal lobe | − 0.014 (0.238) | 0.953 | 0.002 (0.033) | 0.957 | 0.084 (0.159) | 0.595 | − 0.014 (0.039) | 0.595 | − 0.46 (0.18) | 0.012 |
| Parietal GM | − 0.033 (0.149) | 0.824 | 0.027 (0.025) | 0.287 | − 0.033 (0.119) | 0.778 | 0.022 (0.030) | 0.778 | − 0.46 (0.14) | 0.001 |
| Parietal WM | 0.024 (0.139) | 0.863 | − 0.025 (0.018) | 0.161 | 0.121 (0.090) | 0.180 | − 0.038 (0.022) | 0.180 | 0.02 (0.10) | 0.879 |
| Occipital lobe | − 0.137 (0.199) | 0.491 | 0.024 (0.027) | 0.365 | − 0.122 (0.137) | 0.375 | 0.016 (0.033) | 0.375 | − 0.53 (0.15) | < 0.001 |
| Occipital GM | − 0.082 (0.139) | 0.557 | 0.045 (0.024) | 0.059 | − 0.168 (0.119) | 0.158 | 0.039 (0.028) | 0.158 | − 0.59 (0.13) | < 0.001 |
| Occipital WM | − 0.059 (0.091) | 0.513 | − 0.022 (0.012) | 0.065 | 0.036 (0.059) | 0.537 | − 0.020 (0.014) | 0.537 | 0.07 (0.07) | 0.275 |
| Hippocampus | − 0.003 (0.015) | 0.840 | − 0.000 (0.002) | 0.803 | − 0.000 (0.007) | 0.968 | − 0.000 (0.002) | 0.968 | − 0.03 (0.01) | 0.002 |
GM gray matter, WM white matter.
All bolded values mean p-value < 0.01 (using false discovery rate for multiple comparison).
aModel (model 3) adjusted for ICV, the latest diagnostic status, baseline age, sex, race, years of education, height, fat mass, lean mass, number of multi-morbidities, CES-D, APOE e4 status and brisk walking. All β represent the change in brain volumes with 10% increase in baseline/change in cost to capacity ratio.
Figure 1Adjusted baseline and annual change of ventricular volume at years since baseline (index). Solid black lines represent the estimated average if baseline cost-to-capacity ratio = 0.2 (good energy utilization), dashed black lines represent the estimated average volume if baseline cost-to-capacity ratio = 0.5 (moderate energy utilization), and dotted black lines represent the estimated average volume if baseline cost-to-capacity ratio = 0.8 (poor energy utilization). To better see individual trajectories, gray dots and gray lines at the background represent crude individual data points in this study. All estimated averages were fitted using linear mixed effect models after adjustmenta. a Model (model 3) adjusted for ICV, the latest diagnostic status, baseline age, sex, race, years of education, height, fat mass, lean mass, number of multi-morbidities, CES-D, APOE e4 status and brisk walking.